From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)
DOI: 10.1002/dad2.70365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 25.05.2026. Verfasst von Michael Sonson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Cedars-Sinai Medical Center Los Angeles California USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The approval of anti‐amyloid therapies has expanded therapeutic options for patients with Alzheimer's disease (AD), but the pivotal trials that proved their efficacy restrict their applicability to a selected patient population. We describe a case series of seven patients with biomarker‐confirmed AD pathology evaluated in an academic memory clinic and treated with lecanemab whose characteristics would have disqualified them from trial participation. Patient histories and outcomes are presented, accompanied by description of the clinical team's reasoning and application of published Appropriate Use Recommendations for each case. Overall, lecanemab was largely well tolerated, with no unexpected safety concerns and amyloid‐related imaging abnormality rates comparable to trial data. Clinically, most patients remained stable over the treatment period, though some continued to decline. This series highlights the challenges and considerations in applying disease‐modifying therapies beyond trial populations, emphasizing the need for real‐world data to guide treatment in diverse AD presentations.
Autor:innen und Institutionen
- Department of Neurology, Cedars-Sinai Medical Center Los Angeles California USA.
- Jona Goldrich Center for Alzheimer's and Memory Disorders, Cedars-Sinai Medical Center Los Angeles California USA.
- Cedars-Sinai Health Sciences University Los Angeles California USA.
- Department of Pharmacy Services Cedars-Sinai Medical Center Los Angeles California USA.
- Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles California USA.
Zitieren
APA
Sonson, M., Yadollahikales, G., Flores, A., Lasner, I., Lee, S., Tan, Z., Quach, C., & Kremen, S. (2026). From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70365
Vancouver
Sonson M, Yadollahikales G, Flores A, Lasner I, Lee S, Tan Z, et al. From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70365
BibTeX
@article{Sonson2026,
author = {Sonson, Michael and Yadollahikales, Golnaz and Flores, Allison and Lasner, Ilana and Lee, Susan and Tan, Zaldy and Quach, Christina and Kremen, Sarah},
title = {From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {2},
doi = {10.1002/dad2.70365}
}
EUVIMED